ストックスクリーナーアプリを入手
0.7984
1.22%
-0.0099
アフターアワーズ：
.80
0.0016
+0.20%
前日終値:
$0.8083
開ける：
$0.808
24時間の取引高:
45,446
Relative Volume:
0.25
時価総額：
$23.11M
収益：
$26.55M
当期純損益:
$-91.72M
株価収益率:
-0.2228
EPS:
-3.584
ネットキャッシュフロー:
$-13.25M
1週間 パフォーマンス:
+3.69%
1か月 パフォーマンス:
-35.09%
6か月 パフォーマンス:
-54.11%
1年 パフォーマンス:
-60.86%
1日の値動き範囲:
$0.7908
$0.8125
1週間の範囲:
$0.7111
$0.8191
52週間の値動き範囲:
$0.7101
$4.35
Celularity Inc Stock (CELU) Company Profile
Compare CELU vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
0.7984 | 23.40M | 26.55M | -91.72M | -13.25M | -3.584 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-01-30 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2022-12-22 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-06-22 | 開始されました | H.C. Wainwright | Buy |
| 2022-04-06 | ダウングレード | Truist | Buy → Hold |
| 2022-01-28 | 開始されました | Oppenheimer | Outperform |
| 2021-11-24 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Celularity Inc (CELU) 最新ニュース
Celularity Delays Quarterly SEC Filing - TipRanks
Celularity (NASDAQ: CELU) notifies SEC of delayed Q1 2026 10-Q - Stock Titan
TradingKey - TradingKey
Sequence execs join NEXGEL (NASDAQ: NXGL) board after $5.5M note deal - Stock Titan
Celularity regains Nasdaq compliance after delayed filing - MSN
After $5.5M deal backing, Sequence executives take 2 NEXGEL board seats - Stock Titan
NEXGEL Appoints Ian Blackman CFO Amid Celularity Deal - MyChesCo
Celularity Inc. 2025 Annual 10-K Report: Financials, Debt, Equity, and Major Agreements Overview - Minichart
Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation - Investing News Network
Stocks to watch on Friday after hours: CTLP, CELU, ULH (CTLP:NASDAQ) - Seeking Alpha
Celularity Regains Nasdaq Listing Compliance, Shares Rise - marketscreener.com
Celularity regains Nasdaq compliance after filing annual report By Investing.com - Investing.com Australia
Celularity regains Nasdaq compliance after filing annual report - Investing.com
Nasdaq closes Celularity listing case after delayed 10-K filing - Stock Titan
Celularity : Annual Report for Fiscal Year Ending December 31, 2025 (Form 10-K) - marketscreener.com
[10-K] Celularity Inc Files Annual Report - Stock Titan
NEXGEL (NASDAQ: NXGL) hires new CFO to support Celularity deal - Stock Titan
Celularity Inc FY 2025: Revenue $26.6M, EPS $(3.59) — 10-K Summary - TradingView
10-K: FY2025 Annual Report - Moomoo
Celularity Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
NEXGEL Closes Celularity Asset Deal, Launches BioNX Surgical - MyChesCo
NEXGEL expects pro forma annual revenue of roughly $35M following Celularity wound segment acquisition - MSN
Celularity (CELU) Registration Filing Summary - Quartr
NEXGEL Appoints Ian Blackman as Chief Financial Officer - Investing News Network
Nexgel, Inc. Appoints Ian Blackman as Chief Financial Officer - marketscreener.com
NEXGEL taps M&A veteran as CFO to steer Celularity integration - Stock Titan
Inside the deal: After investor bails, Nexgel scrambles to save acquisition that will triple revenue - The Business Journals
Celularity receives Nasdaq notification - MSN
Celularity Inc (CELU) insider Form 3 details warrants and convertible notes - Stock Titan
Celularity Inc (CELU) insider lists warrant and note holdings - Stock Titan
Barach Family Trust (CELU) reports warrants and convertible notes in Celularity Form 3 - Stock Titan
CELU Celularity tops Q3 2025 EPS estimates and posts sharp revenue growth, as shares dip 2.08%.Guidance Upgrade - Cổng thông tin điện tử tỉnh Lào Cai
Celularity (CELU) What Lies Ahead | Celularity Inc posts 42.5% EPS beat, narrower lossDistressed Pick - Cổng thông tin điện tử tỉnh Lào Cai
Celularity (CELUW) Stock: Is It Breaking Uptrend Earnings ReportNCAV - Xã Thanh Hà
CELU (Celularity Inc.) Q3 2025 EPS beats analyst expectations, registers a small post-earnings stock dip.Secondary Offering - Xã Thanh Hà
Family trust reports 20.1% Celularity (CELU) stake from $10M financing - Stock Titan
NEXGEL Reschedules Shareholder Call, Revises Celularity Financing - MyChesCo
NEXGEL closes Celularity biomaterials deal, raises $5.5 million By Investing.com - Investing.com India
Celularity Closes $13.3 Million Asset Sale to NexGel, Strengthening Focus on Longevity Therapeutics and Balance Sheet 1 - Minichart
Celularity Announces Closing of Transaction with NexGel - Investing News Network
Nexgel Inc co and Celularity enter amendment no. 1 to license agreement on April 17, 2026 - marketscreener.com
Nexgel IncCo to Pay Celularity $13.3 Mln I - Moomoo
NexGel Closes Celularity Biomaterials License Terms and Secures $6.9M Convertible Note Financing - TradingView
NEXGEL (NASDAQ: NXGL) triples revenue outlook with Celularity deal, $6.9M notes - Stock Titan
Celularity Inc. announced that it has received $13.3 million in funding from NEXGEL, Inc. - marketscreener.com
NexGel closes acquisition of products from Celularity - TipRanks
NEXGEL New Strategic Partner, Sequence LifeScience, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment - Investing News Network
Celularity Inc (CELU) 財務データ
収益
当期純利益
現金流量
EPS
2.53%
大文字化:
|
ボリューム (24 時間):